Public Board of Directors papers 30 June 2022

Public meeting of the Board of Directors Thursday 26 th May at 12.45 pm Trust meeting room 6 and through virtual access

Present: Chair: Chris Outram (CO), Chairman

Roger Spencer (RS), Chief Executive Officer Kathryn Riddle (KR), Non-executive director Dr Jane Maher (JM), Non-executive Director Robert Ainsworth (RA), Non-executive Director Prof Kieran Walshe (KW), Non-executive Director Grenville Page (GP), Non-executive Director Alveena Malik (AM), Non-executive Director Prof Chris Harrison (CJH), Medical Director and Deputy CEO Bernie Delahoyde (BD), Chief Operating Officer Eve Lightfoot (EL), Director of Workforce Prof Janelle Yorke (JY), Executive Chief Nurse Dr Neil Bayman (NB), Executive Medical Director Sally Parkinson (SP), Interim Director of Finance Prof Richard Fuller (RF), Director of Education

Minutes: Louise Westcott (LW), Company Secretary In attendance: Jo D’Arcy, Assistant Company Secretary

Prof Adrian Bloor, Consultant Haematology Oncology Ruth Clout, Practice Educator Angela Leather, Transplant Coordinator Karen Dodd, Clinical Nurse Specialist, Haem TYA Anne-Marie Hamilton, Clinical Practice Facilitator

Clinical presentation: Professor Adrian Bloor, CAR-T therapy service developments AB introduced the service and noted that Dr Amit Patel was leading this service but very sadly died last year. AB outlined why we deliver CAR-T therapy and the treatment that was previously available to these patients as well as the science behind CAR-T and how they harness patients’ t-cells to fight cancer. CAR-T is a toxic therapy and patients can end up in intensive care. The pathway was outlined, we have been doing this since 2018 and the therapy is relatively new across the whole of Europe. Angela explained that patients are seen in clinic and assessed for fitness for treatment, they go to panel and then come in for harvest of cells. Some patients need interim treatment as the cells take 6 weeks before they come back and are ready to be used for treatment. Karen noted the aphesis process, the patient comes in for collection at 8am, is checked and put onto the machine where lymphocytes are taken from the patient. Ruth explained that once a date is arranged for the treatment they come in for 3 days of chemotherapy and then the infusion of the CAR-T product. The cells are quick to infuse, toxicity is checked and cytokine syndrome and neurological toxicity is monitored. This is intense for the patient for many days. Patients are usually in for about 2 weeks and then followed up. Ruth gave a brief tour of the unit and showed the Board the facilities. AB outlined a patient story of a 23-year-old female who didn’t respond to standard treatment. She was then given CAR-T therapy in 2019 and is now cured. In terms of the UK data, there have been about 800 patients, with 600 treated. There’s an attrition rate as some are not well enough to complete therapy. Activity projections were outlined, we

2